Desirée Thielke

938 total citations · 1 hit paper
12 papers, 701 citations indexed

About

Desirée Thielke is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Desirée Thielke has authored 12 papers receiving a total of 701 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Desirée Thielke's work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (7 papers) and Diabetes Management and Research (4 papers). Desirée Thielke is often cited by papers focused on Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (7 papers) and Diabetes Management and Research (4 papers). Desirée Thielke collaborates with scholars based in Denmark, United States and United Kingdom. Desirée Thielke's co-authors include Juan P. Frías, Andrei‐Mircea Catarig, Nanna L. Lausvig, Carel W. le Roux, Rory J. McCrimmon, Ildiko Lingvay, Bernhard Ludvik, Vaishali Bhosekar, Bernard Zinman and Ingrid Holst and has published in prestigious journals such as Diabetes, Diabetologia and The Lancet Diabetes & Endocrinology.

In The Last Decade

Desirée Thielke

12 papers receiving 686 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

2019 267 citations Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology profile →

Peers

Countries citing papers authored by Desirée Thielke

Since Specialization

Citations

This map shows the geographic impact of Desirée Thielke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Desirée Thielke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Desirée Thielke more than expected).

Fields of papers citing papers by Desirée Thielke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Desirée Thielke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Desirée Thielke. The network helps show where Desirée Thielke may publish in the future.

Co-authorship network of co-authors of Desirée Thielke

This figure shows the co-authorship network connecting the top 25 collaborators of Desirée Thielke. A scholar is included among the top collaborators of Desirée Thielke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Desirée Thielke. Desirée Thielke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes 2021 ·Diabetes Obesity and Metabolism ·John B. Buse, Ingrid Holst, Filip K. Knop, Kajsa Kvist, Desirée Thielke, Richard E. Pratley	4
2	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial 2020 ·Diabetologia ·Rory J. McCrimmon, Andrei‐Mircea Catarig, Juan P. Frías, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke, Ildiko Lingvay	98
3	Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden 2020 ·Diabetologia ·Emelie Andersson, Sofie Persson, (unknown), Åsa Ericsson, Desirée Thielke, Peter Lindgren, Katarina Steen Carlsson, Johan Jendle	59
4	Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden 2020 ·Diabetes Obesity and Metabolism ·Sofie Persson, Pierre Johansen, Emelie Andersson, Peter Lindgren, Desirée Thielke, Brian Larsen Thorsted, Johan Jendle, Katarina Steen Carlsson	20
5	1165-P: Costs of Diabetes Complications: Hospital-Based Care and Production Loss for 392,200 People with Type 2 Diabetes and Matched Controls 2020 ·Diabetes ·Emelie Andersson, Sofie Persson, (unknown), Åsa Ericsson, Desirée Thielke, Peter Lindgren, Katarina Steen Carlsson, Johan Jendle	1
6	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial breakdown → 2019 ·The Lancet Diabetes & Endocrinology ·Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, Ingrid Holst, Bernhard Ludvik, Desirée Thielke, James Thrasher, Vincent Woo, Athena Philis‐Tsimikas	267
7	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial 2019 ·The Lancet Diabetes & Endocrinology ·Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías, Harish Kumar, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke, Adie Viljoen, Rory J. McCrimmon	208
8	Semaglutide Consistently Reduces Cardiovascular Events in Both Male and Female Subjects with Type 2 Diabetes 2018 ·Diabetes ·Irene Hramiak, Cyrus Desouza, Jochen Seufert, Thomas Fritz Hansen, Desirée Thielke, Ildiko Lingvay	1
9	Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach 2018 ·Diabetes Obesity and Metabolism ·Rune Viig Overgaard, Søren Lindberg, Desirée Thielke	23
10	Semaglutide provides superior glycemic control across SUSTAIN 1–5 clinical trials 2018 ·International Journal of Nutrology ·Andrew Ahmann, Francis C. C. Chow, (unknown), (unknown), (unknown), Desirée Thielke, (unknown), (unknown)	7
11	Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5 2017 ·Canadian Journal of Diabetes ·Lawrence A. Leiter, G. Charpentier, Louis Chaykin, Timothy Garvey, Mark Warren, Julie Derving Karsbøl, Desirée Thielke, Luís Masmiquel	8
12	[Orphan drugs--medications for patients with rare diseases]. 2006 ·PubMed ·Desirée Thielke, Jacob P. Thyssen, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact